{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'IWRS:', 'interactive web response system', 'LLN:', 'lower limit of normal', 'mITT:', 'modified intent to treat', 'MRI:', 'magnetic resonance imaging', 'MS:', 'multiple sclerosis', 'NCI:', 'National Cancer Institute', 'NIMP:', 'noninvestigational medicinal product', 'NSAID:', 'nonsteroidal anti-inflammatory drug', 'PD:', 'pharmacodynamic(s)', 'PDCO:', 'Paediatric Committee', 'PI:', 'Principal Investigator', 'PIP:', 'Paediatric Investigation Plan', 'PK:', 'pharmacokinetic(s)', 'PV:', 'pharmacovigilance', 'QoL:', 'quality of life', 'RRMS:', 'relapsing remitting multiple sclerosis', 'SAC:', 'Scientific Advisory Committee', 'SC:', 'subcutaneous(ly)', 'SD:', 'standard deviation', 'SDMT:', 'Symbol Digit Modality Test', 'T1/2z:', 'terminal half-life associated with the terminal slope', 'TB:', 'tuberculosis', 'TEAEs:', 'treatment emergent adverse events', 'Tmax:', 'time to reach Cmax', 'uRTI:', 'upper respiratory tract infection', 'UTI:', 'urinary tract infection', 'WBC:', 'white blood cell', 'Property of the Sanofi Group - strictly confidential', 'Page 30', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '4', 'INTRODUCTION AND RATIONALE', 'Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that affects', 'approximately 2.3 million people worldwide (1). Its clinical course is typically characterized by', 'initial episodes of transient neurological compromise with full recovery, followed by a phase of', 'cumulative deficits that may increase with each new episode. Most patients eventually develop', 'secondary progression leading to a constellation of chronic sequelae including profound muscle', 'weakness, impaired gait and mobility, bladder and bowel dysfunction, and cognitive and visual', 'impairments.', 'MS is typically considered to be a disease of young adults. However, paediatric MS is', 'increasingly recognized and accounts for approximately 5 percent of cases (2, 3, 4). Differential', 'diagnosis includes leukodystrophies, vasculopathies, sarcoidosis, lymphoma, mitochondrial', 'defects, and other metabolic disorders.', 'The estimated prevalence of paediatric patients among all patients with MS ranges between 2.7%', 'to 10.5% (3), and it is estimated that approximately 20% to 25% of children with MS experience', 'breakthrough disease activity that may trigger a switch to another therapy (2,4).', 'The onset of MS in childhood typically occurs during the key formative years. It can restrict', 'school attendance and has the potential to negatively affect the developing neural connections', 'implicated in learning and higher-order information processing. Fatigue may also have a great', 'impact on activities and development.', 'Paediatric MS patients develop disability, as well as shift to the secondary progressive phase of', 'MS, after a longer disease interval but at a younger age, compared with adult MS patients', '(5, 6,7).', 'With increased recognition of paediatric MS worldwide, children are now being treated earlier', 'in their disease course with the goal of limiting long-term disability (8). There is no approved', 'disease modifying therapy (DMT) indicated for paediatric MS and the effects of DMTs in', 'children have not been formally evaluated in controlled clinical trials. The current treatment and', 'prognosis of paediatric MS are based on that of adult patients, because data are limited in', 'paediatric MS and it is assumed that the disease response in children is likely to be similar', '(9, 10, 11, 12).', 'Off label use of medicinal products in children without proper evidence poses an ethical problem.', 'That is why the need for clinical trials with children has now been widely recognised and is', 'stimulated by European Union legislation (EU regulation). Trials of alemtuzumab are therefore', \"necessary in the paediatric population to develop a better knowledge of the drug's effects in\", 'children (safety and efficacy).', 'Property of the Sanofi Group - strictly confidential', 'Page 31', 'VV-CLIN-0254406: 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Alemtuzumab Clinical Data in Adults', 'Alemtuzumab is a humanized monoclonal antibody that targets CD52, a cell surface antigen', 'present at high levels on B and T lymphocytes and at lower levels on natural killer cells,', 'monocytes and macrophages. There is little or no CD52 detected on neutrophils, plasma cells, or', 'bone marrow stem cells. Alemtuzumab acts through antibody-dependent cell-mediated', 'cytotoxicity and complement-dependent cytotoxicity following cell surface binding to T and', 'B lymphocytes. It effects rapid and sustained lymphocyte depletion and has shown potent efficacy', 'in treatment-na\u00efve as well as treatment-refractory patients with relapsing remitting multiple', 'sclerosis (RRMS). Treatment with alemtuzumab 12 mg/day is efficacious in patients with RRMS', 'and was associated with clinically meaningful and statistically significant improvements in', 'clinical endpoints, imaging endpoints and composite disease measures, compared with', 'subcutaneous (SC), high-dose, high-frequency interferon-beta-lalpha (IFNB-1a).', 'MS relapses are caused by focal inflammatory lesions, which are detected by magnetic resonance', 'imaging (MRI) as new or enlarging T2-hyperintense and Gd Gadolinium)-enhancing lesions, in', 'brain or spinal cord. Prior studies have established a strong correlation between relapse outcomes', 'and the occurrence of such lesions (13). A correlation between effects on MRI measures and', 'relapses is also seen in alemtuzumab studies. Table 6 shows the odds ratio for the occurrence of at', 'least one relapse (versus no relapses) for patients who developed at least one new or enlarging', 'T2 lesion (versus no new/enlarging lesions) over the course of the 2-year study period in studies', 'CAMMS323 or CAMMS324. In both studies, a strong and statistically significant relationship is', 'seen between risk of T2 lesions and relapse, with patients being at least 50% more likely to', 'experience relapse if they have MRI lesion activity. These findings demonstrate that the', 'conclusion from prior studies (13) of a strong correlation between this objective MRI outcome', 'and relapse rate applies also to alemtuzumab clinical studies of adult MS patients, and support the', 'use of new/enlarging T2 lesions as a primary efficacy endpoint in the proposed paediatric MS', 'study.', 'Table 6 - MRI correlative analyses with relapse in adult Phase 3 studies (CAMMS323 and', 'CAMMS324)', 'Study CAMMS323', 'Study CAMMS324', 'Endpoint', 'OR', 'p-value', 'OR', 'p-value', 'Gadolinium enhancing lesions at Month 24', '1.58', '0.1217', '2.31', '0.0012', 'New/enlarging T2 lesions over 24 months', '1.54', '0.0312', '1.52', '0.0200', 'New T1 lesions over 24 months', '1.59', '0.0347', '1.69', '0.0078', 'MRI activity over 24 months', '1.53', '0.0384', '1.48', '0.0296', 'Abbreviation: MRI: magnetic resonance imaging; OR: odds ratio', 'Clinical trials with alemtuzumab in adult MS patients have provided a consistent pattern of safety', 'observations that include infusion associated reactions (IARs), autoimmune disorders (thyroid', 'disorders, immune thrombocytopenia [ITP], nephropathies such as antiglomerular basement', 'membrane [antiGBM disease and other cytopenias), and infections. Measures to detect and', 'manage these effects were implemented early and refined throughout the clinical program.', 'These measures enabled the management of patients within the studies and have laid a foundation', 'for the care of patients outside of the clinical trial setting.', 'Property of the Sanofi Group - strictly confidential', 'Page 32', 'VV-CLIN-02544065 5.0']\n\n###\n\n", "completion": "END"}